Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Rationale and design of REAC-TAVI 2: Single antiplatelet treatment with ticagrelor vs aspirin after transcatheter aortic valve implantation.

American heart journal·2025

Same author

Impact of renal function on Ticagrelor-induced antiplatelet effects in coronary artery disease patients.

International journal of cardiology. Heart & vasculature·2023

Same author

Simplified Geleijnse score for identifying chest pain features associated with coronary ischemia.

Heart & lung : the journal of critical care·2023

Same author

Effect of cocoa (<i>Theobroma cacao</i> L.) on platelet function testing profiles in patients with coronary artery disease: ECLAIR pilot study.

Open heart·2022

Same author

Global longitudinal strain assessment of cardiac function and extravascular lung water formation after diving using semi-closed circuit rebreather.

European journal of applied physiology·2022

Same author

The Effect of Dapagliflozin on Platelet Function Testing Profiles in Diabetic Patients: The EDGE Pilot Study.

Cardiology and therapy·2021

Search research articles

Related Experiment Video

Updated: May 19, 2026

Microfluidics in Assessing Platelet Function

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Prasugrel.

Antonio Tello-Montoliu¹, Salvatore D Tomasello, Dominick J Angiolillo

¹University of Florida College of Medicine-Jacksonville, Jacksonville, FL, USA. dominick.angiolillo@jax.ufl.edu

Advances in Cardiology

|August 22, 2012

Summary

This summary is machine-generated.

Prasugrel, a potent P2Y12 inhibitor, significantly reduces ischemic events in acute coronary syndrome patients compared to clopidogrel. However, it increases major bleeding risk, necessitating careful patient selection and potential dose adjustments.

More Related Videos

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

Combination of High Ligation and Intraoperative Embolization Using Polidocanol for Treatment of Varicoceles

Combination of High Ligation and Intraoperative Embolization Using Polidocanol for Treatment of Varicoceles

Published on: December 22, 2023

Related Experiment Videos

Last Updated: May 19, 2026

Microfluidics in Assessing Platelet Function

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

Combination of High Ligation and Intraoperative Embolization Using Polidocanol for Treatment of Varicoceles

Combination of High Ligation and Intraoperative Embolization Using Polidocanol for Treatment of Varicoceles

Published on: December 22, 2023

Area of Science:

Cardiology
Pharmacology
Clinical Medicine

Background:

Prasugrel represents a third-generation thienopyridine antiplatelet agent.
It offers more potent and consistent inhibition of the platelet P2Y12 receptor than clopidogrel.
This enhanced inhibition is crucial for managing patients with acute coronary syndromes (ACS).

Purpose of the Study:

To evaluate the efficacy and safety of prasugrel compared to clopidogrel in ACS patients undergoing percutaneous coronary intervention (PCI).
To identify patient subgroups that benefit most from prasugrel and those at higher risk of adverse events.

Main Methods:

Large-scale phase III clinical trials were conducted.
Patients with high-to-moderate risk ACS undergoing PCI were included.
Outcomes assessed included ischemic events, stent thrombosis, and bleeding risk.

Main Results:

Prasugrel demonstrated a greater reduction in ischemic events, including stent thrombosis, compared to clopidogrel.
An increased risk of major bleeding was observed with prasugrel, particularly in specific patient populations.
Optimal benefit was noted in patients without prior stroke/TIA, aged <75, and weighing >60 kg.

Conclusions:

Prasugrel offers significant ischemic benefits for ACS patients undergoing PCI but carries a higher bleeding risk.
Careful patient selection, considering factors like age, weight, and history of stroke, is essential for maximizing prasugrel's benefit-risk ratio.
Further research and dose modification strategies are needed to optimize prasugrel's clinical utility and safety profile.